

October 2026

Forecasting disease progression with patient digital twins

Somsuvra Chatterjee
CTO Team

Vishwanathan Raman
Co-author

Contents

1. Introduction	3
1.1. Why forecasting disease progression has become a strategic imperative	3
1.2. From digital twin to patient twinning	3
1.3. Types of patient digital twins and application areas	4
2. The data foundation of a patient digital twin	5
2.1. Key data sources for patient digital-twin development	5
3. Modeling disease progression: From longitudinal data to forecastable futures	6
3.1. Approach on disease progression scenario generation through AI	6
3.2. Modeling approaches for patient digital twins	9
4. Digital-twin generators and the shift toward probabilistic virtual patients	10
4.1. Core components of digital twin	10
4.2. Clinical trajectory sample generation flow for — digital twin	11
5. Large language models and the emerging DT-GPT pattern	12
5.1. How a DT-GPT LLM projects clinical-health trajectories	12
6. Why patient twinning matters for clinical-trial optimization	13
6.1. Clinical-trial optimization through digital patient twinning	13
6.2. Value realization through digital patient twinning	15
6.3. Digital-twin applications in the trial and research arena	15
7. Clinical applications and evidence signals in disease areas	16
7.1. Applications of patient digital twin in health	16
7.2. Application of digital twins in the healthcare industry	17
8. The modeling toolbox behind patient twinning	18
8.1. Comprehensive modeling approaches for patient digital twins	18
8.2. AI and mathematical models enabling patient twin simulation, prediction and personalized clinical decision-making	19
9. Data integration, ethics and governance	20
10. Implementation roadmap for healthcare enterprises	21
10.1. Enterprise roadmap for developing, operationalizing and scaling patient — digital-twin capabilities	21
11. Validation, regulatory qualification and reimbursement pathways	22
12. Future outlook	23
12.1. Future outlook for the patient digital twin	24
13. Conclusion	24
14. References	27

1. Introduction

Patient twinning extends the digital-twin concept from industrial systems to human health by building a computational model of an individual patient that evolves with new data and simulates future health states.

When patient twins are built from longitudinal electronic health records, medical images, laboratory values, medications, physiology and contextual signals, they can forecast disease progression, compare intervention scenarios and support more individualized care. The same modeling capability is increasingly relevant to clinical research because digital-twin generators can create virtual control trajectories, support individual-level treatment-effect estimation and help optimize trial design where cost, time and recruitment are major constraints.

The technical landscape now spans multimodal-image-plus-electronic health record (EHR) frameworks, probabilistic generative models of clinical trajectories and large-language-model-enabled systems that forecast clinical variables while adding conversational interpretability. Taken together, these developments position patient digital twins as a practical foundation for precision medicine, longitudinal disease surveillance and more adaptive clinical development.

1.1. Why forecasting disease progression has become a strategic imperative

Disease progression is highly heterogeneous, especially in chronic and complex conditions, which means that patients with the same diagnosis may follow very different clinical trajectories and respond differently to therapy.

Traditional clinical pathways and conventional trial designs often rely on population averages and retrospective evidence, limiting the ability to anticipate the future state of any one individual. Digital twins address this gap by integrating diverse patient signals into an evolving virtual model that can simulate risk, progression and response under different scenarios. For providers, this creates a pathway to earlier intervention and more personalized care. For life sciences organizations, it creates a pathway to better trial design, more precise stratification and improved use of synthetic or augmented controls.


The value of digital twins in disease progression includes:

- **Clinical value:** Earlier visibility of risk, treatment response and likely progression
- **Research value:** Optimized cohorts, protocol simulation and individualized treatment-effect estimation
- **Enterprise value:** Better use of longitudinal data, stronger precision-medicine programs and more scalable digital research operations

1.2. From digital twin to patient twinning

In healthcare, a digital twin is a computational representation of a patient, organ, disease process or physiological system that mirrors its real-world counterpart and can be updated over time.

Patient twinning refers specifically to constructing a virtual counterpart of an individual patient so clinicians and researchers can estimate probable disease trajectories, compare treatments and explore what-if decisions before acting in the physical world. The concept can be applied at multiple biological scopes, from whole-body twins to organ-specific, disease-specific and composite twins that integrate multiple layers of physiology and context.



1.3.Types of patient digital twins and application areas

Table 1: Biological scope and application types of healthcare digital twins

Twin type	Primary focus	Typical use case
Whole-body digital twin	Integrated, person-level physiology and context	Longitudinal risk forecasting and personalized care planning
Organ-specific twin	Heart, lung, brain, liver or other organ systems	Surgical planning, device optimization or organ-level treatment simulation
System/function-specific twin	Specific physiological functions or pathways	Cardiometabolic monitoring, respiratory function or endocrine control
Cellular or subcellular twin	Molecular, cellular or tissue mechanisms	Drug response, mechanism discovery and precision oncology
Disease-specific twin	A defined disease process such as Alzheimer's or diabetes	Forecasting disease progression and tailoring intervention pathways
Composite twin	Combination of multiple biological levels	Complex multi-organ disease modeling and precision-medicine programs

2. The data foundation of a patient digital twin

Effective patient digital twins rely on broad, multimodal and continuously refreshed data. Important inputs include personal clinical and biological data, behavioral and lifestyle data, environmental and societal context, real-time signals from devices and wearables, and population-level epidemiological data.

For disease progression modeling specifically, temporally aligned sequential medical images and structured EHR data such as demographics, medications and laboratory measurements are especially valuable.

In practice, the quality of a digital twin depends on interoperability, temporal alignment and the ability to harmonize different modalities into a coherent patient timeline.

Figure 1: Patient digital-twin data ecosystem



2.1.Key data sources for patient digital-twin development

Table 2: Core data inputs for building effective patient twins


Data category	Examples	Why it matters
Clinical and biological	Diagnosis history, labs, biomarkers, genomics, imaging	Defines baseline health status and disease burden
Behavioral and lifestyle	Diet, exercise, smoking, sleep, adherence	Shapes risk, progression and treatment response
Environmental and societal	Living conditions, pollution, socioeconomic context	Adds external determinants that influence health outcomes
Real-time monitoring	Wearables, sensors, remote monitoring devices	Enables continuous updates and early warning signals
Population-level context	Registries, epidemiological datasets, benchmark cohorts	Improves calibration, generalization and comparative forecasting

3. Modeling disease progression: From longitudinal data to forecastable futures

Patient-specific disease progression frameworks combine sequential medical images with temporally aligned EHR features to model multimodal longitudinal change over time. The core objectives are multimodal fusion, temporal analysis and future prediction, including the ability to generate future images and forecast future EHR metrics. This represents a shift from static classification to dynamic simulation of how disease may evolve under conditions. The approach also addresses limitations of prior methods that relied on imaging only, including insufficient EHR context or failure to represent longitudinal history and future-state generation.

3.1.Approach on disease progression scenario generation through AI

Figure 2: Multimodal disease progression flow



Multimodal disease progression flow: Explanation

This architecture in Figure 2 shows how patient digital twins predict disease progression by combining medical images (for example, MRI, CT, X-ray, retinal scans) with EHR over time.

1. Input data

- Sequential medical images collected across multiple visits
- **EHR data containing:**
 - Static data: age, gender, genetics, medical history
 - Time-varying data: lab results, vitals, medications, symptoms

Goal: Capture a complete longitudinal view of the patient's health.

2. Image registration

Medical images from different time periods are aligned to ensure accurate comparison:

- Global alignment: Corrects rotation, shift and scaling.
- Nonrigid registration: Adjusts for anatomical changes and deformations.

Outcome: All images are spatially aligned, enabling the reliable tracking of disease changes.

3. EHR embedding and fusion

Purpose: Convert structured clinical data into machine-learnable representations.

Methods:

- Embedding layers
- ST-FiLM conditioning
- Global tokens (ViViT)

The model combines Image + Clinical context.


Examples: Blood pressure, tumor markers, medications and disease severity scores

4. Spatio-temporal modeling (core intelligence layer)

The aligned image sequence and EHR history are fed into AI models that learn how disease evolves.

- ConvLSTM (convolutional long short-term memory): Learns spatial and temporal patterns simultaneously.
- ViViT (vision transformer): Uses attention mechanisms to identify important disease progression patterns across time.

Outcome: Learns disease trajectories and future progression patterns.



5. Latent representation

The system creates a shared patient embedding (digital-twin state) that combines:

- Imaging biomarkers
- Clinical variables
- Historical disease progression patterns

Outcome: Unified representation of the patient's current and future health state.

6. Future prediction branches

A. Image generation

Predicts future medical images:

- Direct image forecasting
- CVAE + GAN-based image synthesis

Example: Generate what a retinal scan or brain MRI may look like 6 months later.

B. Clinical variable prediction

Predicts future EHR values using multilayer perceptron (MLP)/fully connected networks:

- Biomarker levels
- Vital signs
- Disease scores
- Lab values

Example: Estimate HbA1c, blood pressure, creatinine or tumor size at future visits.

Final output

The patient twin produces:

- Future medical images with predicted disease manifestations in scans
- Predicted clinical measurements and outcomes

Scenario example with a diabetes patient twin

Inputs:

- Retinal images from 2024 to 2026
- HbA1c history
- Blood glucose records
- Medication data

Model learns relationship between retinal damage and diabetes progression.

Outputs:

- Predicted retinal image for 2027
- Predicted HbA1c = 8.3%
- Risk of diabetic retinopathy progression = High

This effectively creates a living digital twin of the patient, enabling clinicians to simulate future disease states and evaluate intervention scenarios before they occur.

3.2. Modeling approaches for patient digital twins

Table 3: Why integrated patient twinning is needed in disease progression modeling

Model category	Data used	What it does well	Main limitation
Static image-based convolutional neural network (CNN) models	Medical images only	Current-state detection and classification	No temporal progression modeling and no future-state forecasting
Image + limited EHR transformers	Images plus sparse EHR attributes	Basic multimodal fusion	Minimal EHR context and no longitudinal history
MRI-to-MRI prediction models	Baseline imaging	Future image generation	Cannot reflect medication, laboratory or broader clinical effects
Temporal subtraction methods	Prior and current images	Highlights change over time	Enhances diagnosis but does not predict future trajectories
General temporal models	Varies across image and EHR inputs	Time-series modeling	Often do not jointly combine images, EHR and long-term history

Convolutional long short-term memory (ConvLSTM) and video vision transformer (ViViT) represent two prominent spatio-temporal strategies evaluated in recent research for multimodal forecasting that integrates image and EHR data. ConvLSTM offers a more sequential and compute-efficient pathway, while ViViT provides stronger global spatio-temporal modeling and richer multimodal fusion for large, complex datasets.

Table 4: ConvLSTM versus ViViT for patient digital-twin forecasting

Aspect	ConvLSTM	ViViT
Spatial modeling	Local	Global
Temporal modeling	Sequential	Global / parallel
Scalability	Limited	High
Multimodal fusion	Moderate	Strong
Performance on complex patterns	Moderate	High

However, with the advancement of deep-learning neural networks, there have been attempts in various research to arrive at a digital twin using probabilistic neural models such as the Neural Boltzmann Machine (NBM).

4. Digital-twin generators and the shift toward probabilistic virtual patients

Digital-twin generators are conditional generative models of clinical trajectories that can create patient-specific twins from baseline data and forecast how their clinical measurements are likely to evolve over time. A major clinical-trial use case is generating a twin from a participant baseline visit and forecasting how that individual would likely progress on placebo or standard of care using historical controls or disease registries for training.

The probabilistic design is important because clinically useful forecasting must represent not only the expected average path but also variability, uncertainty, time-to-event behavior and multivariate relationships across variables, including:



Autoencoder-based imputation for missing baseline and longitudinal data



Point prediction for expected future clinical values



Variance prediction for uncertainty-aware forecasting



Time-to-event modeling where clinical events are relevant



Neural Boltzmann Machine style generation to preserve joint distributions and correlations

4.1. Core components of a digital twin

Table 5: Core components of a digital-twin generator

Component	Role in the architecture	Why it matters
Imputation module	Reconstructs or fills in missing patient data	Improves robustness in sparse real-world and trial datasets
Point predictor	Forecasts expected future values for longitudinal variables	Provides individualized trajectory estimates
Variance predictor	Estimates dispersion or uncertainty around predictions	Supports probabilistic forecasting rather than single-point prediction
Time-to-event model	Predicts event timing when clinically relevant	Adds practical support for progression and safety endpoints
Generative module	Samples realistic multivariate trajectories	Preserves intervariable relationships and enables virtual control generation

4.2. Clinical trajectory sample generation flow for a digital twin

Figure 3: High-level flow diagram




Figure 3 outlines the end-to-end inference and generation pipeline used to create a patient's digital twin for clinical time series.

1. Input (Time + Patient data)

- Captures the static baseline context (for example, age, sex, genetics, medical history).
- Ingests longitudinal measurements up to the current observation time.
- Specifies the exact target future timestamp to forecast.

2. Feature extractor (MLP/ResNet)

- Processes high-dimensional, multimodal clinical inputs into dense representations.
- The model predicts how a patient's measurements deviate from their baseline state over time, instead of directly predicting the absolute future values. Multilayer perceptron (MLP) extracts nonlinear feature interactions between baseline covariates and time deltas.

3. Predictors (mean, variance, time to event)

- **Mean predictor (μ):** Computes the expected value for each longitudinal variable at the future time point, accounting for temporal decay and autocorrelation.
- **Variance predictor (σ^2):** Estimates the predictive uncertainty of each variable, scaling naturally with the time elapsed between observations.
- **Time-to-event model:** Predicts survival curves or the expected time to specific clinical milestones (such as disease progression or mortality).

4. Neural Boltzmann Machine (NBM) model

- Uses the deterministic outputs (predicted means, variances, latent features) as input parameters.
- Acts as an energy-based generative model to capture multivariate dependencies and cross-variable correlations across mixed continuous and discrete measurements.

5. Future samples

- Generate probabilistic, fully realized patient trajectories via Gibbs sampling or Markov Chain Monte Carlo (MCMC).
- Allow trial designers to run Monte Carlo simulations of the patient's future health trajectory under placebo/standard-of-care conditions.

With further advancement and with the advent of large language models (LLMs), there have been attempts to generate the clinical trajectories through fine-tuned LLMs.

5. Large language models and the emerging DT-GPT pattern

An emerging direction is to use fine-tuned large language models to forecast clinical variable trajectories, providing an interactive explanation layer for clinicians and researchers. This approach may support zero-shot predictions on new variables, generate multiple possible future trajectories and improve interpretability through conversational interfaces. The strategic value is not in replacing multimodal or mechanistic disease models but in making digital twins more usable at the point of decision-making.

5.1. How a DT-GPT LLM projects clinical-health trajectories

Figure 4: DT-GPT style forecasting workflow




Figure 4 illustrates the architecture of a DT-GPT (digital twin-generative pretrained transformer), an LLM-based approach to patient health trajectory forecasting.

Instead of using purely numerical time-series regressors (like classical statistical models or specialized recurrent neural networks [RNNs]), this workflow frames patient digital twinning as an autoregressive natural language generation task.

Steps

1. EHR-to-text (input serialization)

Structured and unstructured EHR data — including lab results, vital signs, diagnoses, medications and clinical notes — are converted into structured, timestamped natural language text (for example, “At Day 0: Glucose 110 mg/dL, Metformin prescribed; At Day 90: HbA1c 7.1%...”).

This text-based serialization bypasses traditional data-engineering bottlenecks like complex multitable feature joins and explicit numerical imputation.

2. Fine-tuned LLM (core foundation model)

A domain-adapted biomedical LLM (for example, fine-tuned on clinical datasets) processes the chronological sequence.

The model leverages its pretrained medical knowledge base and contextual attention mechanisms to understand disease dynamics, drug interactions and temporal dependencies.

3. Trajectory forecasts (digital-twin generation)

The LLM autoregressively generates future health states and clinical values over time.

This generated sequence forms the patient digital twin — a forward-looking virtual representation simulating how the patient’s health metrics are expected to evolve.

4. Downstream capabilities (why LLMs are used here)

The trajectory forecasts branch into two distinct downstream capabilities that traditional numerical black-box models struggle to provide:

- **Explanations (interpretability and rationale)**
 - Because the underlying engine is a language model, it can provide textual clinical rationales for its predictions.
 - It can articulate **why a certain biomarker might spike or drop** (for example, explaining that a deteriorating kidney marker is linked to a newly introduced drug interaction in history).
- **Zero-shot queries (conversational/flexible exploration)**
 - Clinicians and researchers can query the digital twin conversationally about variables, clinical endpoint, or “what-if” counterfactual scenarios that were not explicitly included in the fine-tuning training objectives (for example, asking how a metric would change under an alternative condition).


6. Why patient twinning matters for clinical-trial optimization

Clinical-trial optimization is one of the most strategically important use cases for patient twinning. Digital twins can create virtual control groups, increase statistical power and precision, support individual-level treatment-effect estimation and enable simulated comparisons between therapies. These capabilities are especially important because physical trials are expensive, time-consuming and ethically complex, particularly in vulnerable or hard-to-recruit populations. Used responsibly, patient twinning can reduce some physical-trial burden while improving protocol design, safety planning and interpretation of heterogeneous outcomes.

6.1. Clinical-trial optimization through digital patient twinning

Figure 5: A process flow for clinical-trial optimization with patient twinning





Digital patient twinning optimizes clinical trials in the following ways:

- **Creating virtual control groups:** It generates synthetic control trajectories directly from baseline trial data, reducing the need to recruit large physical placebo cohorts — especially critical in rare, vulnerable or hard-to-recruit populations.
- **Boosting statistical power and precision:** It decreases outcome variance by comparing each patient's observed response with their own digital-twin counterpart, increasing the statistical power and precision of the trial.
- **Supporting individual-level treatment-effect estimation:** It enables the precise estimation of heterogeneous treatment responses by simulating how each individual patient would have progressed without intervention.
- **Simulating comparisons between therapies:** It allows silico benchmarking and simulated comparisons across multiple treatment arms or standard-of-care options before deployment.
- **Simulating protocol and cohort design:** It facilitates virtual stress-testing of protocol designs, inclusion/exclusion criteria and cohort definitions to optimize study feasibility and recruitment strategies.
- **Planning dose and safety:** It simulates safety profiles and risk scenarios across different dosage regimens to improve early adverse-event planning and patient safety management.
- **Reducing trial burden and cost:** It significantly reduces overall trial duration, operational expenses and the ethical complexities associated with placing patients on placebos.

6.2. Value realization through digital patient twining

Table 6: How patient twinning creates value in clinical trials

Value lever	Description	Operational impact
Virtual control groups	Forecasts how participants would likely progress on placebo or standard of care	Can reduce control-group burden and improve interpretability
Baseline stratification	Uses patient-specific context to create better-matched cohorts	Improves balance and precision
Protocol simulation	Tests dosing, visit schedules and cohort assumptions in silico	De-risks study design choices before execution
Individual treatment-effect estimation	Separates likely natural history from treatment-associated change	Improves precision in efficacy interpretation
Safety and nonresponse monitoring	Identifies divergence between expected and observed trajectories	Supports earlier intervention and adaptive decision-making

6.3. Digital-twin applications in the trial and research arena

Table 7: Digital-twin applications across the trial and research value chain

Area	Inputs	Processes	Outputs
Customized treatment and care optimization	Clinical, genomic, imaging and lifestyle data	Simulation, optimization, real-time decisions	Improved diagnosis, real-time monitoring personalized interventions
Operational efficiency and resource management	Patient volume, workflow and hospital systems data	Patient-flow simulation and resource optimization	Optimized flow, staffing adjustments and discharge planning
Medical research and drug development	Trial datasets, EHRs, wearables, physiological data (e.g., heart rate, blood pressure, ECG, oxygen saturation)	Synthetic controls, virtual trials, response modeling	Trial optimization, dosage refinement and safety decision support


7. Clinical applications and evidence signals in disease areas

Digital twins are being explored in the areas of cardiology, neurology, respiratory medicine, metabolic disease, surgery, hospital operations, drug discovery and biomanufacturing. For disease progression forecasting, the most relevant examples are patient-specific use cases in which the twin changes treatment planning, risk monitoring or trial design. Table 8 highlights multiple disease areas where digital twins are already generating measurable signals of value.

7.1.Applications of patient digital twins in healthcare

Table 8: Selected healthcare applications of digital twins and reported outcomes

Area	Inputs	Processes	Outputs
Cardiovascular	Drug safety and arrhythmia	Patient-specific cardiac twins simulate electrophysiology and drug effects for personalized therapy	Reduced atrial fibrillation recurrence and strong cardiotoxicity prediction were summarized in the source material
	Hemodynamic modeling	Computational twins simulate heart function and blood flow	Very low simulation error and real-time monitoring potential
Neurological	Neurodegenerative disease progression	Physics-based or hybrid twins simulate disease propagation and support earlier detection	The source material summarizes early-detection signals and high prediction accuracy in Parkinson's-related work
	Brain tumor analysis	Hybrid machine-learning and digital-twin approaches for imaging and therapy planning	High accuracy with opportunities to reduce treatment intensity or radiation exposure
Respiratory	Monitoring and lung modeling	Multiscale or IoT-enabled twins model lung mechanics and breathing patterns	Strong respiration-rate estimation accuracy in monitoring scenarios
Metabolic and endocrine	Diabetes management	Digital twins combine glucose monitoring and predictive support for insulin and lifestyle decisions	Improved time-in-range and reduced hypoglycemia
Metabolic	Insulin resistance	Multiscale twins integrate metabolism, signaling and body composition	Supports prediction of diet and drug effects on insulin resistance



7.2.Application of digital twins in the healthcare industry

Table 9: Representative digital-twin project implementations in the healthcare industry

Physical entity or domain	Example organization or project	Purpose
Lung	Lexma	Simulate blood and oxygen flow to predict ventilation requirements
Heart	Dassault, Medtronic, Boston Scientific, Food and Drug Administration (FDA)	Customize and optimize cardiac devices
	Siemens Healthineers	Support cardiac resynchronization and heart-function simulation
	Heart Navigator	Support TAVR simulation and surgical planning
Alzheimer’s disease	Unlearn AI	Deliver digital twins of trial controls and individual outcomes
Type 2 diabetes	Cleveland Clinic/Twin Health trial	Compare precision care and standard care
Hospitals	GE Care Command, Siemens Healthineers	Optimize workflow efficiency and operational response
Drug discovery and biomanufacturing	Takeda, Teva, AG Pharmaceuticals	Accelerate discovery and optimize biomanufacturing processes

8. The modeling toolbox behind patient twinning

There is no single mathematical framework for digital twins. Healthcare applications span physics-based models, agent-based models, hybrid multiscale methods, statistical regression and survival models, classical machine learning, deep learning for imaging and time series, graph neural networks and foundation-model approaches. This diversity reflects the fact that disease progression operates across multiple biological and clinical scales. In practice, robust enterprise solutions often combine multiple model types rather than relying on a single algorithmic approach.

8.1. Comprehensive modeling approaches for patient digital twins

Table 10: Methods adopted in building digital twins

Method category	Model type	Healthcare use case	Value created
Physics-based modeling	Continuum models: ordinary differential equation and partial differential equation (ODE/PDE)	Cardiovascular hemodynamic, pharmacokinetics, neurodegeneration	High-fidelity simulation and mechanistic interpretability
Discrete models	Agent-based models	Tumor growth, infectious disease, population interactions	Captures heterogeneity and interaction effects
Hybrid models	Discrete and continuum	Cancer treatment and liver regeneration	Multiscale personalization and tissue-level insight
Dynamic cellular models	Differential-equation systems	Drug response prediction and precision oncology	Supports in silico therapy design
Generative deep learning	VAEs and similar models	Single-cell biology and multi-omics integration	Predicts unseen responses and reduces wet-lab burden
Graph neural networks	Graph-based models	Gene interaction networks and tissue mechanics	Improves representation of biological relationships
Statistical models	Regression and survival models	Risk prediction and oncology survival analysis	Interpretability and baseline clinical decision support
Machine learning	Tree-based models	Disease classification and clinical decision support	Strong performance on noisy healthcare data

Method category	Model type	Healthcare use case	Value created
Deep learning	CNNs, RNNs, transformers	Imaging, ECG, glucose and time-series monitoring	High accuracy and real-time forecasting
Foundation or LLM models	Transformer-based foundation models	Clinical trials and rare disease modeling	Handles sparse data and adds conversational interaction
Pharmacokinetics and pharmacodynamics (PK/PD) models	Compartmental models	Drug-dosing and therapy optimization	Supports personalized dosing strategies
Real-time edge twins	IoT and edge analytics	Remote monitoring and early warning systems	Continuous updates and reduced hospital events

8.2. AI and mathematical models enabling patient-digital-twin simulation, prediction and personalized clinical decision-making

Table 11: Mathematical frameworks and agentic opportunities for patient twinning

Framework	Purpose in digital twins	Example use case	Potential agentic or LLM-enabled role
Logistic regression and predictive models	Estimate disease probability from risk factors	Diabetes or complication risk prediction	Feature selection, explanation and clinical summarization
Differential equations and dynamical systems	Model continuous health change over time	Disease progression trajectory modeling	Dynamic adjustment of equations and what-if simulation
Markov models	Represent transitions between health states	Healthy to pre-disease to disease pathways	Interpret transitions and suggest preventive interventions
Bayesian networks	Model probabilistic dependencies	Gene–protein–disease relationships	Update causal probabilities and explain dependencies
Reinforcement learning	Optimize treatment strategies over time	Drug-dosing optimization	Adaptive decision-making through feedback loops

Framework	Purpose in digital twins	Example use case	Potential agentic or LLM-enabled role
Graph neural networks	Capture complex relationships across data types	Multi-omics plus clinical data fusion	Generate graph explanations and relational queries
RNNs and LSTMs	Analyze longitudinal sequences	Predict hospitalization from history	Trend summarization and anomaly detection
Transformers	Capture long-range dependencies	Longitudinal health prediction	Prioritize historical events and personalize insights
Hybrid AI and mechanistic models	Combine physics-based and AI-driven logic	Full patient twin simulation	Coordinate multiple models in a unified decision layer

9. Data integration, ethics and governance

Data integration is both the fuel and the bottleneck of patient twinning. Digital twins depend on the interoperability of **EHRs, imaging systems, wearables, registries and, sometimes, genomic or laboratory platforms**. Privacy, consent, data ownership, cross-border data handling and compliance with regulations such as **HIPAA and GDPR** remain major deployment constraints. Bias in training data and poor model explainability can also undermine clinician trust and worsen inequities, making multidisciplinary governance essential.

An implementation-ready governance model therefore requires technical safeguards, validation processes, clinician oversight and responsible model monitoring:

- Interoperability standards such as FHIR and HL7 are critical for scalable data exchange.
- Encryption, anonymization and role-based access are necessary for privacy protection.
- Bias testing should cover representation, performance drift and subgroup equity.
- Explainability is important for clinician confidence and auditability.

10. Implementation roadmap for healthcare enterprises

A practical implementation approach begins with selecting a high-value use case in which longitudinal outcomes matter and data availability is sufficient.

The next steps are assembling interoperable data, choosing and validating the right modeling strategy, and embedding the twin into real workflows so that it informs risk forecasts, treatment planning or trial optimization.

Governance at scale should include monitoring, documentation, privacy controls and bias testing.

Organizations that approach patient twinning as an enterprise capability rather than an isolated pilot will be better positioned to scale value over time.

10.1. Enterprise roadmap for developing, operationalizing and scaling patient-digital-twin capabilities

Table 12: Enterprise roadmap for patient twinning

Phase	Primary activities	Success criteria
1. Use-case selection	Identify disease area, business case and measurable outcome	Clear clinical and operational value hypothesis
2. Data foundation	Assemble EHR, imaging, device and contextual data with interoperability design	Usable longitudinal dataset with governance controls
3. Modeling and validation	Select mechanistic, statistical, generative, multimodal or hybrid approach	Demonstrated predictive validity and clinical relevance
4. Workflow integration	Embed twin outputs into care, research or operational processes	Actionable outputs used by clinicians or trial teams
5. Scale and governance	Monitor performance, privacy, bias and lifecycle management	Sustained adoption, trust and repeatable deployment

11. Validation, regulatory qualification and reimbursement pathways

Patient digital twins will move from promising research tools to scalable healthcare products only if they can satisfy four adoption tests: technical and clinical validation, regulatory fit, evidence sufficiency for clinical and payer decision-making, and a viable reimbursement model.

Reporting and validation standards such as TRIPOD+AI, DECIDE-AI and SPIRIT-AI/CONSORT-AI provide useful starting points for judging whether forecasting models are reported transparently, evaluated in live settings and prepared for larger-scale clinical studies. These standards suggest that trustworthy patient twinning requires more than good retrospective accuracy; it also requires evidence on calibration, generalizability, clinical utility, safety, workflow integration and human factors.

From a regulatory perspective, the pathway depends on how the digital twin is positioned. If it is intended to diagnose, predict, recommend or influence care in a medical context, regulators may view it as a form of software-as-a-medical-device. In the United States, the Food and Drug Administration (FDA) positions AI-enabled medical software within established device pathways such as 510(k), De Novo or PMA, while also developing lifecycle guidance for adaptive AI and change control. If the product is framed as clinical decision support (CDS), the FDA's January 2026 guidance becomes especially important because some clinical decision support functions may fall outside the device definition while others remain regulated. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency's software- and AI-as-a-medical-device guidance similarly emphasizes qualification, classification, transparency, adaptivity and postmarket vigilance.

Clinical qualification and payer acceptance require a different evidence layer, not just regulatory clearance. NICE and the NHS AI and Digital Regulations Service make this distinction clear: regulatory evidence is often focused on safety and efficacy, whereas adoption and payer decisions require evidence of relative effectiveness when measured against current care, clinically meaningful outcomes, real-world relevance and cost-effectiveness. For patient digital twins, this means that studies should reflect the actual care settings, populations and comparator pathways in which the twin will be used. It also means that health economic evidence, budget impact and workflow consequences may be necessary alongside predictive performance.

Reimbursement remains one of the least mature but most decisive areas for adoption. In the United States, payment may sometimes be achieved indirectly through service-based reimbursement models such as remote patient monitoring when the twin supports monitoring and care management. In Germany, the DiGA program provides a more explicit digital-health reimbursement route for qualifying applications. Across Europe more broadly, reimbursement pathways remain uneven, with structured processes in some markets and fragmented regional commissioning in others. For digital twins used in clinical trials, reimbursement may instead take the form of sponsor-funded research services, protocol-optimization services or evidence-generation partnerships rather than direct clinical payment.

12. Future outlook

Digital twins are expected to become more multimodal, more accurate and more tightly connected to real-time care delivery. Likely advances include stronger AI and machine-learning integration, deeper use of multi-omics data, closed-loop systems linked to wearables, wider EHR integration and more mature virtual clinical trials.

An effective digital twin needs:


- **Personal data (clinical and biological):** Detailed health and biological information (for example, medical records, lab results, genetics) that define an individual's health status
- **Behavioral and lifestyle data:** Information about daily habits (for example, diet, exercise, smoking) that influence health outcomes
- **Environmental and societal data:** External factors such as living conditions, pollution and socioeconomic context that impact health
- **Real-time monitoring data:** Continuous data from devices (for example, wearables, sensors) that track health dynamically over time
- **Population (epidemiological) data:** Aggregated data on diseases and risk factors across groups used to understand trends and improve predictions

The long-term shift is from static prediction to continuously updated simulation, where clinicians and researchers can test likely interventions on a virtual counterpart before acting in the real world. The organizations that succeed will likely be those that combine scientific rigor, interoperable data, model governance and workflow integration.



12.1. Future outlook for the patient digital twin

Figure 6: Outlook on effective digital twins



13. Conclusion

Patient twinning is moving from being a promising concept to becoming a practical architecture for forecasting disease progression and improving both care delivery and clinical research. Its value lies in the combination of multimodal longitudinal data, advanced forecasting models and the simulation of future patient states under alternative scenarios. For providers, this means more personalized intervention and earlier visibility of risk. For life sciences organizations, it means better trial optimization, more intelligent use of controls and a richer understanding of patient heterogeneity. As the field matures, the strongest deployments will be those that translate sophisticated modeling into trustworthy, workflow-ready decisions.

List of abbreviations

Abbreviation	Meaning
AI	artificial intelligence
CDS	clinical decision support
CMS	Centers for Medicare & Medicaid Services
CNN	convolutional neural network
ConvLSTM	convolutional long short-term memory
DECIDE-AI	Developmental and Exploratory Clinical Investigations of Decision-support systems driven by AI
DiGA	Digitale Gesundheitsanwendungen (Digital Health Applications, Germany)
DT	digital twin
DT-GPT	digital twin-generative pretrained transformer (LLM-based digital-twin framework)
EHR	electronic health record
ECG	electrocardiogram
ESF	Evidence Standards Framework
FDA	Food and Drug Administration
FHIR	Fast Healthcare Interoperability Resources
GDPR	General Data Protection Regulation
GE	General Electric
HIPAA	Health Insurance Portability and Accountability Act
HL7	Health Level Seven International
IoT	Internet of things
JMIR	Journal of Medical Internet Research
LLM	large language model
LSTM	long short-term memory
MHRA	Medicines and Healthcare products Regulatory Agency (UK)
MLP	multilayer perceptron
MRI	magnetic resonance imaging
NBM	Neural Boltzmann Machine
NHS	National Health Service (UK)
NICE	National Institute for Health and Care Excellence (UK)
ODE	ordinary differential equation
PDE	partial differential equation
PK	pharmacokinetics
PD	pharmacodynamics
PMA	premarket approval

Abbreviation	Meaning
ResNet	residual neural network
RNN	recurrent neural network
SaMD	software as a medical device
SPIRIT-AI	Standard Protocol Items: Recommendations for Interventional Trials – Artificial Intelligence Extension
TAVR	transcatheter aortic valve replacement
TRIPOD+AI	Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis + Artificial Intelligence
VAE	variational autoencoder
ViViT	video vision transformer

Healthcare and research terms

Abbreviation	Meaning
multi-omics	Integration of genomics, proteomics, metabolomics and other biological datasets
in silico	Simulation performed using computers rather than physical experiments
arrhythmia	Irregular heart rhythm
hemodynamics	Study of blood flow in the cardiovascular system
cardiotoxicity	Toxic effect on the heart
precision medicine	Personalized treatment based on patient-specific characteristics



14. References

- Alam, Nameyeh, Jake Basilico, Daniele Bertolini, Satish Casie Chetty, Heather D'Angelo, Ryan Douglas, Charles K. Fisher, et al. "Digital Twin Generators for Disease Modeling." arXiv, May 2, 2024.
<https://doi.org/10.48550/arXiv.2405.01488>.
- Centers for Medicare and Medicaid Services. "Remote Patient Monitoring." Last modified May 13, 2026.
<https://www.cms.gov/medicare/coverage/telehealth/remote-patient-monitoring>.
- Collins, Gary S., Karel G. M. Moons, Paula Dhiman, Richard D. Riley, Andrew L. Beam, Ben Van Calster, Marzyeh Ghassemi, et al. "TRIPOD+AI Statement: Updated Guidance for Reporting Clinical Prediction Models That Use Regression or Machine Learning Methods." BMJ 385 (2024): e078378.
<https://www.bmj.com/content/385/bmj-2023-078378>.
- Cruz Rivera, Samantha, Xiaoxuan Liu, An-Wen Chan, Alastair K. Denniston, and Melanie J. Calvert, on behalf of the SPIRIT-AI and CONSORT-AI Working Group. "Guidelines for Clinical Trial Protocols for Interventions Involving Artificial Intelligence: The SPIRIT-AI Extension." BMJ 370 (2020): m3210.
<https://doi.org/10.1136/bmj.m3210>.
- Eriş, Hasan Ali, Muhammed Ali Aydın and Mehmet Ali Ertürk. "Toward Patient-Specific Digital Twin Models of Disease Progression Using Sequential Medical Imaging and EHR Data." Applied Sciences 16, no. 4 (2026): 2104.
<https://doi.org/10.3390/app16042104>.
- Fisher, Charles K. "Creating Patients' Digital Twins with Neural Boltzmann Machines for Clinical Timeseries." Unlearn.AI Blog, July 24, 2023.
<https://www.unlearn.ai/blog/creating-patients-digital-twins-with-neural-boltzmann-machines-for-clinical-timeseries>.
- Katsoulakis, Evangelia, Qi Wang, Huanmei Wu, Leili Shahriyari, Richard Fletcher, Jinwei Liu, Luke Achenie, et al. "Digital Twins for Health: A Scoping Review." npj Digital Medicine 7, no. 1 (2024): 77.
<https://doi.org/10.1038/s41746-024-01073-0>.
- Khoshfekar Rudsari, Hamid, Becky Tseng, Hongxu Zhu, Lulu Song, Chunhui Gu, Abhishikta Roy, Ehsan Irajizad, Joseph Butner, James Long and Kim-Anh Do. "Digital Twins in Healthcare: A Comprehensive Review and Future Directions." Frontiers in Digital Health 7 (2025): 1633539. <https://doi.org/10.3389/fdgth.2025.1633539>.
- Liu, Xiaoxuan, Samantha Cruz Rivera, David Moher, Melanie J. Calvert, and Alastair K. Denniston, on behalf of the SPIRIT-AI and CONSORT-AI Working Group. "Reporting Guidelines for Clinical Trial Reports for Interventions Involving Artificial Intelligence: The CONSORT-AI Extension." BMJ 370 (2020): m3164. <https://doi.org/10.1136/bmj.m3164>.
- Makarov, Nikita, Maria Bordukova, Papichaya Quengdaeng, Daniel Garger, Raul Rodriguez-Esteban, Fabian Schmich and Michael P. Menden. "Large Language Models Forecast Patient Health Trajectories Enabling Digital Twins." npj Digital Medicine 8 (2025): 588.
<https://doi.org/10.1038/s41746-025-02004-3>.
- National Institute for Health and Care Excellence. "Evidence Standards Framework for Digital Health Technologies." Corporate document ECD7. Published December 10, 2018. Last updated August 9, 2022.
<https://www.nice.org.uk/what-nice-does/digital-health/evidence-standards-framework-esf-for-digital-health-technologies>.
- Pothireddy, Nirup Kumar Reddy. "GenAI-Powered Digital Twins for Chronic Disease Management." International Journal for Multidisciplinary Research 7, no. 2 (2025).
<https://doi.org/10.36948/ijfmr.2025.v07i02.40878>.
- Ringeval, Mickaël, Faustin Armel Etindele Sosso, Martin Cousineau and Guy Paré. "Advancing Health Care With Digital Twins: Meta-Review of Applications and Implementation Challenges." Journal of Medical Internet Research 27 (2025): e69544.
<https://doi.org/10.2196/69544>.
- U.S. Food and Drug Administration. "Artificial Intelligence in Software as a Medical Device." Accessed September 9, 2026.
<https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device>.
- Vallée, Alexandre. "Digital Twins for Personalized Medicine Require Epidemiological Data and Mathematical Modeling: Viewpoint." Journal of Medical Internet Research 27 (2025): e72411. <https://doi.org/10.2196/72411>.
- Vasey, Baptiste, Myura Nagendran, Bruce Campbell, David A. Clifton, Gary S. Collins, Spiros Denaxas, Alastair K. Denniston, et al. "Reporting Guideline for the Early-Stage Clinical Evaluation of Decision Support Systems Driven by Artificial Intelligence: DECIDE-AI." Nature Medicine 28, no. 5 (2022): 924-933. <https://doi.org/10.1038/s41591-022-01772-9>.

Visit nttdata.com to learn more.

NTT DATA is a \$30+ billion business and technology services leader in AI and digital infrastructure. We accelerate client success and positively impact society through responsible innovation. As a Global Top Employer, we have experts in more than 70 countries. NTT DATA is part of NTT Group.



